BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ryvu Therapeutics SA readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ryvu Therapeutics SA's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06987058-2851@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Romaciclib: Phase 2 readout est. (NCT06987058)
DESCRIPTION:Romaciclib\, phase 2\, Acute Myeloid Leukemia.\nStudy: RVU120 R
 ollover Study\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/romaciclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06987058
URL:https://assetmemo.bio/drug/romaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191263-2851@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Romaciclib: Phase 2 readout est. (NCT06191263)
DESCRIPTION:Romaciclib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Safety a
 nd Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/R
 efractory AML\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/romaciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06191263
URL:https://assetmemo.bio/drug/romaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
